Nasdaq auph.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17.Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) shares are trading higher, adding to gains of more than 17% over the last week.Aurinia Pharmaceuticals (NASDAQ:AUPH) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, institutional ownership, media sentiment, dividends, risk, analyst …During the last session, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares were 2.07 million, with the beta value of the company hitting 1.26. At the end of the trading day, the stock’s price was $8.64, reflecting an intraday gain of 0.47% or $0.04. The 52-week high for the AUPH share is ...Nov 24, 2021 · Every investor in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see ...

Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAurinia Pharmaceuticals (NASDAQ:AUPH) is a company that specializes in developing treatments for diseases that currently have few treatment options. They focus on autoimmune, kidney, and rare ...

Agios Pharmaceuticals (NASDAQ:AGIO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ...

View live Aurinia Pharmaceuticals Inc chart to track its stock's price action. Find market predictions, AUPH financials and market news.Total cost of sales and operating expenses for the quarter ended September 30, 2023 was $70.8 million and $65.3 million for the quarter ended September 30, 2022. Total cost of sales and operating ...Aurinia Pharmaceuticals (NASDAQ:AUPH) could see prices in the high $20s to low $30s per share in a takeout at premium multiples, according to RBC, after the company announced Thursday it was ...Agios Pharmaceuticals (NASDAQ:AGIO) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, community ranking, dividends, valuation, media sentiment, analyst recommendations and institutional ...

Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...

Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ...

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors (“the Board”) has appointed Dr ...NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...Nov 27, 2023 · Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement ... Aurinia Pharmaceuticals Inc. NASDAQ: AUPH gapped up in heavy volume on the first trading day of the year and hasn’t looked back since. The Canadian biotech company launched LUPKYNIS two years ago as the first FDA-approved oral treatment for adults with active lupus nephritis (LN). This autoimmune disease affects more than …AUPH Earnings Date and Information. Aurinia Pharmaceuticals last issued its quarterly earnings data on November 2nd, 2023. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.08. The company had revenue of $54.52 million for the quarter, compared to the consensus estimate of $38 ...Jan 5, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) recently announced they have reached a settlement with Sun Pharmaceuticals (OTCPK:SMPQY) to dismiss their claims and counterclaims against each other.

The new research reports from Fundamental Markets, available for free download at the links above, examine Shinhan Financial Group Co Ltd (NYSE:SHG), Aurinia Pharmaceuticals Inc (NASDAQ:AUPH ...Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock option expenses where possible. Nasdaq provides visual representation of analyst expected ...Aurinia Pharmaceuticals Inc stock price (AUPH) NASDAQ: AUPH. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Aurinia Pharmaceuticals Inc stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Real time Aurinia Pharmaceuticals (AUPH) stock price quote, stock graph, news & analysis.Nov 30, 2023 · See the latest Aurinia Pharmaceuticals Inc stock price (AUPH:XNAS), related news, valuation, dividends and more to help you make your investing decisions. Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. Find real-time AUPH - Aurinia Pharmaceuticals Inc stock quotes,...

Given this risk, we thought we'd take a look at whether Aurinia Pharmaceuticals (NASDAQ:AUPH) shareholders should be worried about its cash burn. …Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)’s traded shares stood at 0.69 million during the latest session, with the company’s beta value hitting 1.28. At the last check today, the stock’s price was $9.28, to imply an increase of 2.66% or $0.24 in intraday trading.

Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2023 Earnings Call Transcript November 2, 2023 Aurinia Pharmaceuticals Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.17. Operator: Greetings. Welcome to Aurinia Pharmaceuticals Third Quarter 2023 Earnings Call. At this time, all participants are in a …Aurinia Pharmaceuticals ( NASDAQ: AUPH) has been on a roll this year since their second quarter earnings in August. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin ...Principal Financial Group Inc. cut its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 8.4% in the 2nd quarter, according to its most recent filing with the ...Market Capitalization. $1.24 billion. P/E Ratio. N/A. Dividend Yield. N/A. Price Target. $14.00. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media.Home AUPH • NASDAQ Aurinia Pharmaceuticals Inc Follow Share $9.06 After Hours: $9.03 (0.33%) -0.030 Closed: Dec 1, 7:57:38 PM GMT-5 · USD · NASDAQ · Disclaimer search …The new research reports from Market Source Research, available for free download at the links above, examine Haverty Furniture Companies, Inc. (NYSE:HVT), BLACKLINE INC (NASDAQ:BL), MagnaChip ...

Nov 29, 2023 · The average twelve-month price prediction for Aurinia Pharmaceuticals is $14.00 with a high price target of $15.00 and a low price target of $13.00. Learn more on AUPH's analyst rating history. Do Wall Street analysts like Aurinia Pharmaceuticals more than its competitors?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is certainly one of the US-listed biotech stocks with significant upside potential as this Canadian biotechnology company, having bolstered its patent ...

Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ...(NASDAQ: AUPH) Aurinia Pharmaceuticals currently has 143,608,164 outstanding shares. With Aurinia Pharmaceuticals stock trading at $8.23 per share, the total value of Aurinia Pharmaceuticals stock (market capitalization) is $1.18B .Find the latest news headlines from Aurinia Pharmaceuticals Inc Ordinary Shares (AUPH) at Nasdaq.com.Aurinia Pharmaceuticals (NASDAQ: AUPH) will report its Q2 2021 earnings after the closing bell today and investors will want to pay attention to sales and any color management provides on its ...Caiaimage/Paul Bradbury. Aurinia Pharmaceuticals ( NASDAQ: AUPH) has begun to examine strategic alternatives that could include a potential sale or merger. The pharma has retained JP Morgan as ...It has been quite some time since we last took a look at Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). This small biopharma has been somewhat of a roller coaster ride for its shareholders in recent ...Dec 4, 2023 · Year-to-date, Rivian Automotive Inc shares have moved -4.45%, while the 5-day performance has seen it change 5.70%. Over the past 30 days, the shares of Rivian Automotive Inc (NASDAQ:RIVN) have changed 0.11%. Short interest in the company has seen 103.62 million shares shorted with days to cover at 2.62. Wall Street analysts have a consensus ... Dec 3, 2021 · Shares of Aurinia Pharmaceuticals Inc. AUPH gained 13.2% on Dec 2, following fresh rumors of a potential buyout. Reportedly, Swiss pharma giant Novartis NVS is looking out for small bolt-on ... Aurinia Pharmaceuticals (NASDAQ:AUPH) has been subject to buyout speculations for well over a year now. It was as early as May 2021, when The Times mentioned AstraZeneca ( AZN ) or GSK ( GSK ) are ...

Fintel reports that on September 22, 2023, HC Wainwright & Co. reiterated coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a Buy recommendation. Analyst Price Forecast Suggests 72.67% Upside ...Anyone who held Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) over the last year knows what a loser feels like. The share price has slid 66% in that time. The share price has slid 66% in that time.Last month, AUPH's second largest shareholder, MKT Capital, which holds 4.2% of the stock, wrote a scathing letter to shareholders, calling to withdraw support for CEO Peter Greenleaf, board ...Instagram:https://instagram. grubhub stocksadidas company stockmetwest total return bond fundfree stock scanner We feel now is a pretty good time to analyse Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) business as it appears the company may be on the cusp of a …Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed the following analyst ratings: Menu icon A vertical stack of three evenly spaced horizontal lines. aftermarket screenerschd holdings full list Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders Insiders own 2.02% of the company shares, while shares held by institutions stand at 60.74% with a share float percentage of 61.99%. Investors are also buoyed by the number of investors in a company, with Aldeyra Therapeutics Inc having a total of 142 institutions that hold shares in the ...Aurinia Pharmaceuticals Inc stock price live 8.64, this page displays NASDAQ AUPH stock exchange data. View the AUPH premarket stock price ahead of the market session or assess the after hours quote. best free dividend tracker Dec 1, 2023 · AUPH Stock Overview. Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. About the company. AUPH fundamental analysis. VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will release financial and operational results for third ...